• Adjuvant treatments include: 5-fluorouracil administered together with folinic acid, or more recently, oral fluoropyrimidines such as capecitabine, in combination with oxaliplatin or irinotecan. (biomedcentral.com)
  • Capecitabine (Xeloda ® ) is an oral fluoropyrimidine which is produced as a pro-drug of fluorouracil, and shows improved tolerability and intratumor drug concentrations following its tumor-specific conversion to the active drug. (wjgnet.com)
  • It is also involved in the degradation of the chemotherapeutic drugs 5-fluorouracil and tegafur. (wikipedia.org)
  • Used as first line therapy for patients with metastatic colorectal cancer when fluoropyrimidine alone is preferred. (indiangenericprice.com)
  • 1,2] For this reason, our cooperative group has focused on fluoropyrimidines modulated by leucovorin as therapy for advanced gastric cancer. (cancernetwork.com)
  • S1, an oral fluoropyrimidine anticancer agent, is widely used for the treatment of unresectable and/or metastatic gastric cancer and for adjuvant chemotherapy after potentially curable resection of stage II/III gastric cancer in Japan [ 1 ]. (springeropen.com)
  • For patients with unresectable tumors, treatment with fluoropyrimidine- or taxane-based chemoradiotherapy (category 1 recommendation) or chemotherapy is acceptable. (medscape.com)
  • S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall survival (OS) and is associated with lower hematologic toxicity. (cancerbiomed.org)
  • S-1 is an oral fluoropyrimidine agent that consists of tegafur, 5- chloro-2, 4-dihydroxypyridine, and potassium oxonate. (bvsalud.org)
  • Vasospastic angina is a rare but potentially life-threatening adverse event (AE) of S1, an oral fluoropyrimidine anticancer agent. (springeropen.com)
  • Accordingly, S-1 is a convenient oral alternative treatment for advanced PDAC. (cancerbiomed.org)
  • S-1 consists of the oral fluoropyrimidine prodrug tegafur and the enzyme inhibitors gimeracil and oteracil. (medscape.com)
  • Fluoropyrimidine carbamate prodrug from of 5-fluorouracil (5-FU). (medscape.com)
  • Dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF), the oral form prodrug of 5-flurouracil (5-FU), has been developed since 1980 [ 10 ], and is currently the most important chemotherapeutic agent used in adjuvant chemotherapy for advanced gastric cancer. (biomedcentral.com)
  • S-1 is an oral prodrug of fluorouracil (5-FU) with 2 biochemical modulators (gimeracil = 5-chloro-2, 4-dihydroxypyridine inhibiting 5-FU degeneration by dihydroxypyridine dehydrogenase, and oteracil = potassium oxonate which reduces the incidence of gastrointestinal toxicity by suppressing the activation of 5-FU in the gastrointestinal tract) [ 1 ]. (hindawi.com)
  • S-1 is an oral anticancer agent containing tegafur, a metabolically activated prodrug of 5-FU, and 2 biochemical modulators [ 1 ]. (hindawi.com)
  • Introduction: S-1 is an oral fluoropyrimidine anticancer drug that contains tegafur, gimeracil, and oteracil potassium. (ersjournals.com)
  • Adjuvant tegafur-gimeracil-oteracil (S-1) is commonly used for gastric cancer in Asia, and tegafur-uracil (UFT) is another oral fluoropyrimidine when S-1 is unavailable. (biomedcentral.com)
  • Tegafur-uracil (UFT) is the first generation of oral DPD DIF, followed by tegafur-gimeracil-oteracil (S-1), the next generation of oral DPD DIF. (biomedcentral.com)
  • S-1 is a synthetic compound containing tegafur, gimeracil (which inhibits the 5-fluorouracil (5-FU) degradation enzyme), and oteracil (which reduces gastrointestinal toxicity) ( 9 - 11 ). (iiarjournals.org)
  • In the European Union, tegafur/gimeracil/oteracil is indicated for the treatment of advanced gastric cancer when given in combination with cisplatin. (alleviareindia.com)
  • Teysuno contains the active substances tegafur, gimeracil and oteracil. (alleviareindia.com)
  • What is Tegafur/gimeracil/oteracil used for? (alleviareindia.com)
  • Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, and also for the treatment of head and neck cancer, colorectal cancer, non-small-cell lung, breast, pancreatic, and biliary tract cancers. (alleviareindia.com)
  • Tegafur/gimeracil/oteracil (Teysuno) was approved for medical use in the European Union in March 2011. (alleviareindia.com)
  • What are the facts of Teysuno (Tegafur/gimeracil/oteracil)? (alleviareindia.com)
  • Drug (Brand / Generic): Teysuno / tegafur, gimeracil and oteracil. (alleviareindia.com)
  • For Teysuno (tegafur/gimeracil/oteracil) capsules Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions. (alleviareindia.com)
  • How to get access Teysuno (tegafur/gimeracil/oteracil) capsules in India? (alleviareindia.com)
  • Confirmation of the order for Teysuno (tegafur/gimeracil/oteracil) capsules will be subject to the submission of a valid doctor's prescription and, if applicable, an import permit. (alleviareindia.com)
  • ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand Teysuno (tegafur/gimeracil/oteracil) capsules. (alleviareindia.com)
  • For patients from following foreign countries seeking access to Teysuno (tegafur/gimeracil/oteracil) capsules , they can inquire and find further information by sending their inquiries to ALS. (alleviareindia.com)
  • October 31, 2007 - A trial from Japan involving 1059 patients has shown that adjuvant treatment with the oral fluoropyrimidine product S-1 (Taiho Pharmaceuticals) improves overall survival in patients with curative resected gastric cancer. (medscape.com)
  • The fluoropyrimidine 5-fluorouracil remains the backbone of chemotherapy regimens for colon cancer, both in the adjuvant and metastatic setting. (medscape.com)
  • Although both UFT and S-1 are indicated for advanced gastric cancer as adjuvant monotherapy in Taiwan, real-world experiences and comparisons of efficacy and tolerance between these two oral DPD DIFs remain suboptimal and are only limited to sub-group analysis in one clinical trial, the Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) [ 15 ]. (biomedcentral.com)
  • The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) resection. (biomedcentral.com)
  • Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection. (biomedcentral.com)
  • In the entire patient cohort, no significant differences were observed in 5-year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3-year recurrence-free survival (RFS) rates (49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine-based adjuvant chemotherapy or observation. (biomedcentral.com)
  • Fluoropyrimidine-based adjuvant chemotherapy may prolong the survival of patients with stages II and III BTC after R0 resection. (biomedcentral.com)
  • Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. (nih.gov)
  • 7. Alternate-day oral therapy with TS-1 for advanced gastric cancer. (nih.gov)
  • 11. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. (nih.gov)
  • 14. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. (nih.gov)
  • Recently, development of novel anticancer drugs such as camptothecins, taxanes, third-generation platinum, and new oral fluoro-pyrimidines has improved the clinical outcomes of patients with unresectable and recurrent gastric cancer ( 5 - 13 ). (iiarjournals.org)
  • 1,2] For this reason, our cooperative group has focused on fluoropyrimidines modulated by leucovorin as therapy for advanced gastric cancer. (cancernetwork.com)
  • It belongs to a group of cancer medicines called fluoropyrimidines and is used to treat advanced gastric (stomach) cancer together with cisplatin (another cancer medicine). (alleviareindia.com)
  • Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. (cdc.gov)
  • It has been shown that the breast cancer is sensitive to the most anti-tumour medicines, especially to doxorubicin and epirubicin (efficacy in 40-50% of patients with the metastatic breast cancer), methotrexate (efficacy in 35% of patients), fluorouracil and tegafur (efficacy in 25-34% of patients). (crimsonpublishers.com)
  • In addition to 5-fluorouracil, oral fluoropyrimidines such as capecitabine (Xeloda) and, outside the United States, tegafur are used as monotherapy or in combination with oxaliplatin (Eloxatin). (medscape.com)
  • It is also involved in the degradation of the chemotherapeutic drugs 5-fluorouracil and tegafur. (wikipedia.org)
  • 8. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. (nih.gov)
  • It is also used to treat metastatic colorectal cancer (cancer of the colon and rectum that has spread elsewhere in the body) in patients who can no longer be treated with other fluoropyrimidines because of unacceptable side effects. (alleviareindia.com)
  • The safety profiles of oral fluoropyrimidines were compared with 5-fluorouracil (5-FU) using adverse event reports (AERs) submitted to the Adverse Event Reporting System, AERS, of the US Food and Drug Administration (FDA). (nih.gov)
  • After a revision of arbitrary drug names and the deletion of duplicated submissions, AERs involving 5-FU and oral fluoropyrimidines were analyzed. (nih.gov)
  • Binds to and stabilizes ternary complex of FdUTP (intracellular active metabolite of fluoropyrimidines) and thymidylate synthetase (TS), augmenting cytotoxic effects of 5-fluorouracil. (medscape.com)